Skip to content

The Sleeping Well Trial: enhancing the effectiveness of continuous positive airway pressure (CPAP) treatment with a weight management program for overweight adults

Increasing the effectiveness of treatment with continuous positive airways pressure (CPAP) using a weight-management program in overweight adults with sleep apnoea : the Sleeping Well Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000203459
Enrollment
60
Registered
2016-02-16
Start date
2016-03-22
Completion date
2017-05-31
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study has been designed to elucidate when is the optimal time to introduce weight management to newly diagnosed patients with OSA who are about to commence on standard care which is overnight CPAP. We have designed this trial to have a step wedge element so that each person will be exposed to the intervention over a 12 month period. To address aim 1) Primary outcome (weight) as measured during each month during the control and intervention periods of the stepped wedge design will be compared between periods. The main effect of the intervention will be examined using a multilevel, mixed effects, linear mixed model analysis approach. Fixed effects will be included in this model for “time” and “intervention”, while a random effect will be included for the effect of “participant”. To address aim 2) We will examine the association between lifestyle intervention commencement month and weight at 12 month follow-up (adjusted for baseline weight). This analysis will treat "lifestyle intervention commencement month" as a continuous variable and examine both a linear and quadratic relationship with the outcome. This design has certain advantages over standard randomized controlled trials which include enabling every participant to be exposed to the intervention and that the impact of time is assessed. This design consists of an initial period, where no one is exposed to the intervention. Eventually, at regular intervals (the “steps”) one cluster (one group) will be randomised to cross from the control to the intervention under evaluation.

Interventions

To address aim 1) Primary outcome (weight) as measured during each month during the control and intervention periods of the stepped wedge design will be compared between periods. The main effect of the intervention will be examined using a multilevel, mixed effects, linear mixed model analysis approach. Fixed effects will be included in this model for “time” and “intervention”, while a random effect will be included for the effect of “participant”. To address aim 2) We will examine the associati

To address aim 1) Primary outcome (weight) as measured during each month during the control and intervention periods of the stepped wedge design will be compared between periods. The main effect of the intervention will be examined using a multilevel, mixed effects, linear mixed model analysis approach. Fixed effects will be included in this model for “time” and “intervention”, while a random effect will be included for the effect of “participant”. To address aim 2) We will examine the association between lifestyle intervention commencement month and weight at 12 month follow-up (adjusted for baseline weight). This analysis will treat "lifestyle intervention commencement month" as a continuous variable and examine both a linear and quadratic relationship with the outcome. CPAP treatment: All CPAP implementation will be provided centrally for all patients by Air Liquide Healthcare. Patients will undergo mask fitting and education regarding sleep apnoea and CPAP use by staff at Air Liquide. Patients will initially be commenced on Autotitrating CPAP using a Resmed S9 CPAP machine. After 1 week of treatment, patients will be switched to fixed pressure CPAP based on the 95th centile pressure determined during the autotitration week. Routine equipment troubleshooting will be provided by Air Liquide, in conjunction with the patient’s treating physician. Patients will undergo routine CPAP care co-ordinated by their physician. All decisions regarding any treatment changes will be made by the treating physician. Participants are required to use their CPAP devices regularly for 12 months period (beginning from consent date). Lifestyle Intervention: All participants will be exposed to the 6-month weight management program. The wait list time for starting treatment will differ with subjects randomised to wait 1,2,3,4,5 or 6 months before they commence. The Intervention is a dietitian delivered face to face intervention comprising of a 1 hour initial appointment followed up by monthly 30 minute consultations. Dietary energy will be reduced using a tailored approach with a 12 week active weight loss phase followed by a 12 week transfer to weight maintenance phase the duration of each phase will be dependant on how much weight each participant has to lose and their success, which is monitored monthly by body weight. The use of an App to extend the reach of the face to face sessions will be utilised. The App allows the participant to connect virtually with their dietitian to report hurdles, feelings or mood that may affect their progress towards their goals. The dietitian can communicate via a pre-defined pathway of text messages which are sent to the participant to motivate them to continue to meet their 'small steps'. Activity is encouraged with 3 x 30 minutes per week of light/ moderate physical activity. Compliance is measured for activity via a wrist worn monitor (Fitbit) which records minute by minute activity on a website which the participant consents to the research team being able to access. Dietary recording is used to monitor compliance with meal plans and agreed nutrient goals. Compliance with CPAP treatment is recorded individually and is inbuilt into each CPAP machine, as minutes per day that it is used.

Sponsors

Monash University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
19 Years to 68 Years
Healthy volunteers
No

Inclusion criteria

Adults aged 19-68 years who have been newly diagnosed with moderate-severe untreated OSA with AHI greater than 20 events/hr (AASM alternate criteria) (demonstrated by prior overnight polysomnography [PSG]). Participants must be overweight with a body mass index (BMI) for Caucasians between 25 and 43 kg/m2 and for those of Asian and Indian descent 23 and 43 and self report a sedentary lifestyle ((self-reported exercise less than 2 days/week and a duration of less than 45 minutes per session. Eligible participants are required to be eligible to use Fixed-Pressure Continuous Positive Airway Pressure (CPAP).

Exclusion criteria

1. Pregnant women 2. Diagnosed with concomitant obesity hypoventilation syndrome, Diabetes mellitus type 1, severe psychiatric disorder, and drowsiness 3. Required to use "VPAP" or "BPAP" (variable/bilevel positive airway pressure) 4. Unable to exercise (e.g. due to orthopedic or musculoskeletal problems) 5. Previous surgical or current medical treatment for OSA 6. Previous bariatric surgery 7. Current use of weight loss programs and/or weight loss drugs 8. Recent angina pectoris or atrial fibrillation 9. Insufficient knowledge of English language to be able to consent 10. Unable to provide informed consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 24, 2026